Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to $284.1 million.

  • Myriad Genetics' Cost of Revenue rose 1.57% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $284.1 million, marking a year-over-year decrease of 13.04%. This contributed to the annual value of $284.1 million for FY2024, which is 1.76% down from last year.
  • Latest data reveals that Myriad Genetics reported Cost of Revenue of $284.1 million as of FY2024, which was down 1.76% from $289.2 million recorded in FY2023.
  • Over the past 5 years, Myriad Genetics' Cost of Revenue peaked at $289.2 million during FY2023, and registered a low of $157.5 million during FY2020.
  • In the last 3 years, Myriad Genetics' Cost of Revenue had a median value of $284.1 million in 2024 and averaged $280.0 million.
  • As far as peak fluctuations go, Myriad Genetics' Cost of Revenue declined by 6.36% in 2020, and later soared by 43.67% in 2022.
  • Yearly analysis of 5 years shows Myriad Genetics' Cost of Revenue stood at $157.5 million in 2020, then reached $157.9 million in 2020, then grew by 17.61% to $185.7 million in 2021, then skyrocketed by 43.67% to $266.8 million in 2022, then climbed by 8.40% to $289.2 million in 2023, then decreased by 1.76% to $284.1 million in 2024.